MedTrace Logo

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

NCT07071701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19267

Last updated 2025-07-17

No results posted yet for this study

Summary

An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.

Conditions

  • Pneumococcal Infectious Disease

Interventions

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine

BIOLOGICAL

Influenza vaccine

Influenza vaccine

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-02
Primary Completion
2024-04-05
Completion
2024-04-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07071701 on ClinicalTrials.gov